June 2013
Volume 54, Issue 15
Free
ARVO Annual Meeting Abstract  |   June 2013
Evaluation of response to Carboplatin in putative Cancer Stem Cells of Retinoblastoma Y79 cell line
Author Affiliations & Notes
  • Geeta Vemuganti
    School of Medical Sciences, University of Hyderabad, Hyderabad, India
  • Rohini Nair
    School of Medical Sciences, University of Hyderabad, Hyderabad, India
  • Murali Mohan Sagar Balla
    Ophthalmic Pathology Laboratory, L.V.Prasad Eye Institute, Hyderabad, India
  • Santosh Honavar
    Ophthalmic and Facial Plastic Surgery, Orbit and Ocular Oncology, L.V.Prasad Eye Institute, Hyderabad, India
  • Mohammad Ali
    Ophthalmic and Facial Plastic Surgery, Orbit and Ocular Oncology, L.V.Prasad Eye Institute, Hyderabad, India
  • Vijay Anand Palkonda
    Apollo Cancer Hospital, Hyderabad, India
  • Footnotes
    Commercial Relationships Geeta Vemuganti, None; Rohini Nair, None; Murali Mohan Sagar Balla, None; Santosh Honavar, None; Mohammad Ali, None; Vijay Anand Palkonda, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2013, Vol.54, 1256. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Geeta Vemuganti, Rohini Nair, Murali Mohan Sagar Balla, Santosh Honavar, Mohammad Ali, Vijay Anand Palkonda; Evaluation of response to Carboplatin in putative Cancer Stem Cells of Retinoblastoma Y79 cell line. Invest. Ophthalmol. Vis. Sci. 2013;54(15):1256.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract
 
Purpose
 

Evaluation of Cancer Stem Cells (CSCs) in primary tumors is not only of academic interest but of potential therapeutic application. Due to the technical challenges in working with primary cells, this study attempts to evaluate the response to standard Rb chemotherapeutic agent, Carboplatin in the putative CSC population of Retinoblastoma Y79 cell line. With the preliminary evidence that CD133- FSClo/SSClo cells could be putative Cancer stem cells in Y79 cell line, we evaluated the cytotoxicity of these cells to Carboplatin.

 
Methods
 

Phenotypic characterization and sorting of cultured Y79 cells was done by FACS Aria II using putative CSC marker CD133. The sorted cells and total cells were analyzed for response to various doses (0-100μM) of Carboplatin (Alkem Pharmaceuticals) following 48 hr exposure. Controls consisted of untreated cells from CD133± and total Y79 cells. Cell death was observed under phase contrast microscope and the wells were treated with MTT(5mg/ml), the resulting formazan crystals were dissolved with DMSO and absorbance was read at 570nm. A comparative analysis of percentage of viability among the three groups- total Y79 cells, CD133+ and CD133- cells was done using GraphPad Prism .

 
Results
 

Retinoblastoma Y79 cell lines when sorted using CD133 revealed 3.8% CD133+ and 16.2% CD133- of total viable Y79 cells. CD133- cells showed increased resistance and proliferation compared to CD133+ and unsorted cells (p<0.01) following 48 hr exposure to higher doses of Carboplatin indicating chemoresistance in this population. Maximum proliferation (151.57±37.54%) was observed at 50µM in CD133- cells . At the same dose, the viability of total Y79 cells and CD133+ cells were 39.66±3.05 and 65.22±10.12 respectively.

 
Conclusions
 

The study shows that the Y79 CD133- FSClo/SSClo cells exhibit resistance to high dose Carboplatin with increased proliferation as compared to controls. This is in concordance with our previous findings of quiescence, clonal nature and gene expression (ARVO abstract no 2643/A450) in putative Cancer Stem Cells of Retinoblastoma Y79 cell line.

 
 
Drug response of CD133 positive, negative and total Y79 cells treated with various concentrations of Carboplatin for 48 hours by MTT Assay
 
Drug response of CD133 positive, negative and total Y79 cells treated with various concentrations of Carboplatin for 48 hours by MTT Assay
 
Keywords: 703 retinoblastoma • 529 flow cytometry • 503 drug toxicity/drug effects  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×